<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – January 13, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”), is pleased to announce a second amendment (the “Amendment”) to the research and license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) for the performance of studies evaluating the efficacy of its CBD-Loaded Liposome Platform Technology (LPT) in treating dogs. The Amendment was signed…
...read full article on Newsfile Corp
